TW202342048A - 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 - Google Patents
使用ｌｏｕ０６４治療化膿性汗腺炎之方法 Download PDFInfo
- Publication number
- TW202342048A TW202342048A TW112107010A TW112107010A TW202342048A TW 202342048 A TW202342048 A TW 202342048A TW 112107010 A TW112107010 A TW 112107010A TW 112107010 A TW112107010 A TW 112107010A TW 202342048 A TW202342048 A TW 202342048A
- Authority
- TW
- Taiwan
- Prior art keywords
- lou064
- treatment
- patient
- patients
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263314572P | 2022-02-28 | 2022-02-28 | |
| US63/314,572 | 2022-02-28 | ||
| US202263369016P | 2022-07-21 | 2022-07-21 | |
| US63/369,016 | 2022-07-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202342048A true TW202342048A (zh) | 2023-11-01 |
Family
ID=85570288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW112107010A TW202342048A (zh) | 2022-02-28 | 2023-02-24 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250099465A1 (https=) |
| EP (1) | EP4486346A1 (https=) |
| JP (2) | JP7696006B2 (https=) |
| KR (1) | KR20240155278A (https=) |
| CN (1) | CN120617264A (https=) |
| AU (1) | AU2023225222A1 (https=) |
| CA (1) | CA3251002A1 (https=) |
| IL (1) | IL314205A (https=) |
| MX (1) | MX2024010392A (https=) |
| TW (1) | TW202342048A (https=) |
| WO (1) | WO2023161887A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| LT3380465T (lt) | 2015-11-26 | 2020-11-10 | Novartis Ag | Diamino piridino dariniai |
| JOP20190053A1 (ar) | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| JP7007374B2 (ja) | 2016-09-23 | 2022-01-24 | ノバルティス アーゲー | 腱及び／又は靭帯損傷に使用するためのインダゾール化合物 |
| CN112512527A (zh) * | 2018-09-12 | 2021-03-16 | 杭州索元生物医药股份有限公司 | 恩扎妥林和btk抑制剂的组合及其用途 |
| MX2021014161A (es) | 2019-05-23 | 2022-01-04 | Novartis Ag | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. |
| HRP20251001T1 (hr) | 2019-05-23 | 2025-10-24 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u liječenju kronične spontane urtikarije |
| BR112021023054A2 (pt) * | 2019-05-23 | 2022-03-29 | Novartis Ag | Formas cristalinas de um inibidor de btk |
| TW202142237A (zh) * | 2020-01-08 | 2021-11-16 | 美商普林斯匹亞生物製藥公司 | 包含2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1h-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4,4-二甲基戊-2-烯腈之局部醫藥組成物 |
| TWI905371B (zh) | 2021-01-26 | 2025-11-21 | 瑞士商諾華公司 | 藥物組成物 |
-
2023
- 2023-02-24 TW TW112107010A patent/TW202342048A/zh unknown
- 2023-02-27 IL IL314205A patent/IL314205A/en unknown
- 2023-02-27 US US18/729,542 patent/US20250099465A1/en active Pending
- 2023-02-27 KR KR1020247031567A patent/KR20240155278A/ko active Pending
- 2023-02-27 EP EP23710457.5A patent/EP4486346A1/en active Pending
- 2023-02-27 AU AU2023225222A patent/AU2023225222A1/en active Pending
- 2023-02-27 WO PCT/IB2023/051787 patent/WO2023161887A1/en not_active Ceased
- 2023-02-27 CA CA3251002A patent/CA3251002A1/en active Pending
- 2023-02-27 JP JP2023553381A patent/JP7696006B2/ja active Active
- 2023-02-27 MX MX2024010392A patent/MX2024010392A/es unknown
- 2023-02-27 CN CN202511059211.7A patent/CN120617264A/zh active Pending
-
2025
- 2025-06-09 JP JP2025095960A patent/JP2025134747A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4486346A1 (en) | 2025-01-08 |
| JP2024511938A (ja) | 2024-03-18 |
| JP7696006B2 (ja) | 2025-06-19 |
| WO2023161887A1 (en) | 2023-08-31 |
| IL314205A (en) | 2024-09-01 |
| CA3251002A1 (en) | 2023-08-31 |
| MX2024010392A (es) | 2024-09-06 |
| US20250099465A1 (en) | 2025-03-27 |
| KR20240155278A (ko) | 2024-10-28 |
| AU2023225222A1 (en) | 2024-07-25 |
| JP2025134747A (ja) | 2025-09-17 |
| CN120617264A (zh) | 2025-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6974669B2 (ja) | Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬 | |
| KR102258698B1 (ko) | B-Raf 억제제와 제2 억제제를 포함하는 조합 요법 | |
| US7879870B2 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
| CN107982270A (zh) | 治疗乳腺癌的方法 | |
| CN116059365A (zh) | 对使用维甲酸受体-α激动剂治疗的患者进行分层的方法 | |
| EP3972604A1 (en) | Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor | |
| JP2023057151A (ja) | Ａｍｌ及びｍｄｓの治療のためのｒａｒａアゴニスト | |
| JP2024511141A (ja) | オリスミラストによる化膿性汗腺炎の治療 | |
| JP2010508277A (ja) | 癌を検出および抑制するための方法 | |
| JP2025134747A (ja) | 化膿性汗腺炎の治療における使用のためのレミブルチニブ | |
| KR20220088830A (ko) | 비뇨기계암의 치료 방법 | |
| Xiang et al. | Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis | |
| KR102675587B1 (ko) | 펜벤다졸, 옥시벤다졸 또는 이들의 혼합물을 포함하는 자궁내막 세포 또는 영양막 세포의 비정상적 증식 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| JP2024525515A (ja) | がんの予防用又は治療用の医薬組成物 | |
| Lu et al. | Flutamide inhibits nifedipine‐and interleukin‐1β‐induced collagen overproduction in gingival fibroblasts | |
| JP7594124B2 (ja) | Ｌｏｕ０６４を使用した治療の方法 | |
| EA051701B1 (ru) | Ремибрутиниб для применения в лечении гнойного гидраденита | |
| CN118742308A (zh) | 用于在治疗化脓性汗腺炎中使用的雷米布鲁替尼 | |
| US20250339442A1 (en) | Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor | |
| WO2025217284A1 (en) | Methods and compositions for treating inflammatory and autoimmune disorders of the skin | |
| CN117479936A (zh) | 用奥瑞司特治疗化脓性汗腺炎 | |
| Marren et al. | THU0173 Pregnancy Outcomes in the Tofacitinib RA Safety Database Through April 2014 | |
| TW202539668A (zh) | 使用索樂匹尼布處置免疫性血小板減少症的方法 | |
| EA051816B1 (ru) | Способы лечения с применением lou064 | |
| JP2021511380A (ja) | 腫瘍増殖を抑制するためのミナプリンの使用 |